Q2 EPS Estimates for Surmodics Cut by Barrington Research

Key Points

• Barrington Research has revised down its Q2 2026 earnings per share (EPS) estimates for Surmodics to $0.00, down from a previous forecast of $0.01, maintaining a "Market Perform" rating on the stock.
• Surmodics reported a quarterly EPS of $0.06 for the last quarter, surpassing the consensus estimate of ($0.21) by $0.27, indicating some positive performance despite lowered future expectations.
• Hedge funds and institutional investors continue to hold significant stakes in Surmodics, with 96.63% of the company owned by these entities, reflecting strong institutional interest despite the recent earnings forecast adjustments.

Surmodics, Inc. (NASDAQ:SRDX - Free Report) - Equities research analysts at Barrington Research decreased their Q2 2026 earnings per share estimates for shares of Surmodics in a note issued to investors on Monday, August 11th. Barrington Research analyst M. Petusky now expects that the company will earn $0.00 per share for the quarter, down from their prior estimate of $0.01. Barrington Research currently has a "Market Perform" rating on the stock. The consensus estimate for Surmodics' current full-year earnings is $0.20 per share. Barrington Research also issued estimates for Surmodics' Q3 2026 earnings at $0.00 EPS and Q4 2026 earnings at $0.06 EPS.

Surmodics (NASDAQ:SRDX - Get Free Report) last issued its earnings results on Friday, August 8th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.21) by $0.27. The business had revenue of $29.57 million during the quarter, compared to the consensus estimate of $28.04 million. Surmodics had a negative return on equity of 2.99% and a negative net margin of 14.59%.

A number of other equities research analysts have also recently weighed in on SRDX. Needham & Company LLC restated a "hold" rating on shares of Surmodics in a report on Wednesday, April 30th. Zacks Research upgraded Surmodics to a "hold" rating in a report on Tuesday. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat.com, Surmodics has a consensus rating of "Hold" and a consensus target price of $43.00.

Surmodics Price Performance

Shares of SRDX traded down $0.18 on Tuesday, reaching $37.46. The stock had a trading volume of 408,956 shares, compared to its average volume of 266,417. The firm has a market capitalization of $535.68 million, a PE ratio of -30.46 and a beta of 1.31. The company has a quick ratio of 3.10, a current ratio of 3.91 and a debt-to-equity ratio of 0.27. The firm has a 50-day moving average of $32.08 and a 200 day moving average of $30.89. Surmodics has a twelve month low of $26.00 and a twelve month high of $40.38.

Institutional Investors Weigh In On Surmodics

A number of large investors have recently bought and sold shares of the stock. Millennium Management LLC grew its holdings in Surmodics by 0.4% during the 4th quarter. Millennium Management LLC now owns 120,344 shares of the company's stock valued at $4,766,000 after buying an additional 509 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of Surmodics by 67.6% during the second quarter. BNP Paribas Financial Markets now owns 1,435 shares of the company's stock worth $43,000 after purchasing an additional 579 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in shares of Surmodics by 1.8% during the first quarter. Principal Financial Group Inc. now owns 36,699 shares of the company's stock worth $1,120,000 after purchasing an additional 638 shares during the last quarter. Legal & General Group Plc boosted its holdings in shares of Surmodics by 34.2% during the fourth quarter. Legal & General Group Plc now owns 3,452 shares of the company's stock worth $137,000 after purchasing an additional 880 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its holdings in shares of Surmodics by 705.9% during the second quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company's stock worth $37,000 after purchasing an additional 1,080 shares during the last quarter. Institutional investors and hedge funds own 96.63% of the company's stock.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).